-
Mashup Score: 104
PURPOSE Allogeneic hematopoietic stem-cell transplantation (HSCT) is the only potentially curative treatment for patients with myelodysplastic syndromes (MDS). Several issues must be considered when evaluating the benefits and risks of HSCT for patients with MDS, with the timing of transplantation being a crucial question. Here, we aimed to develop and validate a decision support system to define the optimal timing of HSCT for patients with MDS on the basis of clinical and genomic information as provided by the Molecular International Prognostic Scoring System (IPSS-M). PATIENTS AND METHODS We studied a retrospective population of 7,118 patients, stratified into training and validation cohorts. A decision strategy was built to estimate the average survival over an 8-year time horizon (restricted mean survival time [RMST]) for each combination of clinical and genomic covariates and to determine the optimal transplantation policy by comparing different strategies. RESULTS Under an IPSS-M
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 95
PURPOSE Allogeneic hematopoietic stem-cell transplantation (HSCT) is the only potentially curative treatment for patients with myelodysplastic syndromes (MDS). Several issues must be considered when evaluating the benefits and risks of HSCT for patients with MDS, with the timing of transplantation being a crucial question. Here, we aimed to develop and validate a decision support system to define the optimal timing of HSCT for patients with MDS on the basis of clinical and genomic information as provided by the Molecular International Prognostic Scoring System (IPSS-M). PATIENTS AND METHODS We studied a retrospective population of 7,118 patients, stratified into training and validation cohorts. A decision strategy was built to estimate the average survival over an 8-year time horizon (restricted mean survival time [RMST]) for each combination of clinical and genomic covariates and to determine the optimal transplantation policy by comparing different strategies. RESULTS Under an IPSS-M
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14'24 Move for MDS: Tampa - 1 month(s) ago
Move for MDS 2023
Source: secure.qgiv.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 53Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes - 2 month(s) ago
MicroabstractTriple-negative myelofibrosis (MF) constitutes a distinct disease subset marked by aggressive clinical features, higher rates of leukemic transformation, shorter duration of response to ruxolitinib and poor survival. Mutations affecting epigenetic modification, RNA splicing and signaling likely drive its hostile course and may account for suboptimal responses to JAK inhibition.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 53Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes - 2 month(s) ago
MicroabstractTriple-negative myelofibrosis (MF) constitutes a distinct disease subset marked by aggressive clinical features, higher rates of leukemic transformation, shorter duration of response to ruxolitinib and poor survival. Mutations affecting epigenetic modification, RNA splicing and signaling likely drive its hostile course and may account for suboptimal responses to JAK inhibition.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 53
The patterns of low risk myelodysplastic syndrome (MDS) progression, and the clinical and molecular features of those patterns are not well described. We divided our low risk (LR) MDS patients (n=1914) into 4 cohorts: 1) Patients who remained LR-MDS (LR-LR; n=1300; 68%), 2) Patients who progressed from LR to HR MDS (LR-HR) without AML transformation (n=317; 16.5%), 3) Patients who progressed from LR to HR MDS and then AML (LR-HR-AML; n=124; 6.5%), 4) Patients who progressed from LR MDS to AML directly (LR-AML; n=173; 9%). Risk factors for progression included male gender, low absolute neutrophil count (ANC), low platelet count, high bone marrow (BM) blasts, ferritin >1000 mcg/L, albumin
Source: haematologica.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 114
Imetelstat offers a novel mechanism of action with durable transfusion independence (approximately 1 year) and disease-modifying activity for heavily transfused patients with LR-MDS who are not responding to or are ineligible for ESAs.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 109
Imetelstat offers a novel mechanism of action with durable transfusion independence (approximately 1 year) and disease-modifying activity for heavily transfused patients with LR-MDS who are not responding to or are ineligible for ESAs.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes - Leukemia - 1 year(s) ago
The Molecular International Prognostic Scoring System (IPSS-M) is a novel risk stratification model for myelodysplastic syndromes (MDS) that builds on the IPSS and IPSS-R by incorporating mutational data. The model showed improved prognostic accuracy over the IPSS-R across three endpoints: overall survival (OS), leukemia-free survival (LFS) and leukemic transformation. This study aimed to…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1MPN-MDS US - 1 year(s) ago
Kimpton Hotel Palomar Phoenix, Arizona Save The Date: April 28-29 The Co-chairs of the 2023 MPN-MDS US Focus Meeting are: Prithviraj Bose, MDMD…
Source: mpn-mds2023.md-education.comCategories: Hem/Oncs, Latest HeadlinesTweet
Honored to be co-senior author on this effort led by Dr Della Porta combining GenoMed and Moffitt database. @MoffittNews Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of AHSCT in Pts With MDS | Journal of Clinical Oncology https://t.co/nOfI9g6fyt